Human Growth Hormone Market in the US 2015-2019

米国のヒト成長ホルモン市場2015-2019

◆タイトル:Human Growth Hormone Market in the US 2015-2019
◆商品コード:IRTNTR5538
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年3月25日
◆ページ数:84
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:米国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、米国のヒト成長ホルモン市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、米国のヒト成長ホルモン市場規模及び予測、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Human Growth Hormone
Human growth hormone, also known as somatotropin, is a peptide with 191 amino acids and 2 sulfhydryl bridges. It is produced by the anterior pituitary, and it is required to attain normal size for children and adolescents. It also has major effects on lipid and carbohydrate metabolism of an individual. The effects of human growth hormone are mainly mediated by IGF-1 and IGF-2. There are two forms of recombinant human growth hormone approved in the market: Somatropin and Somatrem. Somatropin has 191 amino acids and Somatrem contains 192 amino acids. Growth hormone deficiency can occur either due to a damage to the pituitary or the hypothalamus gland, or can also be acquired genetically. Some of the signs of growth hormone deficiency are adiposity, short stature, and hypoglycemia.

TechNavio’s analysts forecast the Human Growth Hormone market in the US to grow at a CAGR of 3.86 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Human Growth Hormone market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the various human growth hormone drugs available in the US for the treatment of growth hormone deficiency.

TechNavio’s report, the Human Growth Hormone Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Human Growth Hormone market in the US and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key Vendors]
• F. Hoffmann-La Roche
• Merck Serono
• Novo Nordisk
• Pfizer

[Other Prominent Vendors]
• Eli Lilly
• Teva Pharmaceutical
• Novartis
• Ipsen

[Market Driver]
• Demand for Human Growth Hormone
• For a full, detailed list, view our report

[Market Challenge]
• High Cost of Therapy
• For a full, detailed list, view our report

[Market Trend]
• Growing Focus on Needle-free Drug Delivery Devices
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Human Growth Hormone: An Overview
06.1 Human Growth Hormone
06.2 Pharmacological Action of Human Growth Hormone
06.3 Therapeutic Uses of Human Growth Hormone
06.4 Growth Hormone Deficiency
06.4.1 Childhood-onset Growth Hormone Deficiency
06.4.2 Adult-onset Growth Hormone Deficiency

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Buying Criteria

09.Market Growth Drivers

10.Drivers and their Impact

11.Market Challenges

12.Impact of Drivers and Challenges

13.Market Trends

14.Trends and their Impact

15.Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Market Share Analysis 2014
15.2.1 Novo Nordisk
15.2.2 Pfizer
15.2.3 Merck Serono
15.2.4 F. Hoffmann-La Roche
15.3 Other Prominent Vendors

16.Key Vendor Analysis
16.1 F. Hoffmann-La Roche Ltd.
16.1.1 Key Facts
16.1.2 Business Overview
16.1.3 Business Segmentation
16.1.4 Business Segmentation by Revenue 2012 and 2013
16.1.5 Sales by Geography
16.1.6 Business Strategy
16.1.7 Key Information
16.1.8 SWOT Analysis
16.2 Merck Serono
16.2.1 Key Facts
16.2.2 Business Overview
16.2.3 Geographical Segmentation by Revenue 2013
16.2.4 Business Strategy
16.2.5 Recent Developments
16.2.6 SWOT Analysis
16.3 Novo Nordisk A/S
16.3.1 Key Facts
16.3.2 Business Overview
16.3.3 Business Segmentation by Revenue 2013
16.3.4 Business Segmentation by Revenue 2012 and 2013
16.3.5 Sales by Geography
16.3.6 Business Strategy
16.3.7 Key Information
16.3.8 SWOT Analysis
16.4 Pfizer
16.4.1 Key Facts
16.4.2 Business Overview
16.4.3 Business Segmentation by Revenue 2013
16.4.4 Business Segmentation by Revenue 2012 and 2013
16.4.5 Geographical Segmentation by Revenue
16.4.6 Business Strategy
16.4.7 Key Developments
16.4.8 SWOT Analysis

17.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Structure of Human Growth Hormone
Exhibit 3: Clinical Uses of Recombinant Human Growth Hormone
Exhibit 4: Regulation of Human Growth Hormone and its Effects
Exhibit 5: Types of Growth Hormone Deficiency
Exhibit 6: Human Growth Hormone Market in US 2014-2019 (US$ million)
Exhibit 7: Drivers of Human Growth Hormone Market in US
Exhibit 8: NovoFine Needle
Exhibit 9: NordiPenMate
Exhibit 10: Challenges in Human Growth Hormone Market
Exhibit 11: Trends in Human Growth Hormone Market
Exhibit 12: Market Share of Vendors 2014
Exhibit 13: Comparison of Market Share of Major Drugs 2014 (US$ million)
Exhibit 14: YoY Global Revenue and Growth Rate of Norditropin 2012-2014 (US$ million)
Exhibit 15: Dosage Strengths of FlexPro
Exhibit 16: Dosage Strengths of NordiFlex
Exhibit 17: Dosage Strengths of Norditropin NordiLet
Exhibit 18: Dosage Strengths of Nordipen
Exhibit 19: Diagrammatic Illustration of Nordipen
Exhibit 20: Genotropin Miniquick
Exhibit 21: Diagrammatic Illustration of Genotropin Miniquick
Exhibit 22: Genotropin Mixer
Exhibit 23: Parts of Genotropin Mixer
Exhibit 24: Genotropin Pen
Exhibit 25: Diagrammatic Illustration of Genotropin Pen
Exhibit 26: YoY Global Revenue and Growth Rate of Genotropin 2011-2013 (US$ million)
Exhibit 27: YoY Global Revenue and Growth Rate of Saizen 2011-2013 (US$ million)
Exhibit 28: Diagrammatic Illustration of Click.easy
Exhibit 29: Easypod Drug Delivery Device
Exhibit 30: Diagrammatic Illustration of Cool.click 2
Exhibit 31: One.click Drug Delivery Device
Exhibit 32: Serojet Drug Delivery Device
Exhibit 33: YoY Global Revenue and Growth Rate of Nutropin 2010-2013 (US$ million)
Exhibit 34: Comparison of Global and US Revenue of Nutropin 2012 and 2013 (US$ million)
Exhibit 35: Diagrammatic Illustration of Nutropin AQ NuSpin
Exhibit 36: Nutropin AQ NuSpin 10
Exhibit 37: Nutropin AQ NuSpin 20
Exhibit 38: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 39: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 40: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 41: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 42: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 43: Novo Nordisk A/S: Business Segmentation by Revenue 2013
Exhibit 44: Novo Nordisk A/S: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 45: Novo Nordisk A/S: Sales by Geography 2013
Exhibit 46: Pfizer: Business Segmentation by Revenue 2013
Exhibit 47: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 48: Pfizer: Geographical Segmentation by Revenue 2013



【掲載企業】

F. Hoffmann-La Roche , Merck Serono, Novo Nordisk , Pfizer , Eli Lilly, Teva Pharmaceutical, Novartis, Ipsen

【資料のキーワード】

ヒト成長ホルモン、ソマトトロピン、医薬品、治療

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[米国のヒト成長ホルモン市場2015-2019] (Human Growth Hormone Market in the US 2015-2019 / IRTNTR5538)販売に関する免責事項
[米国のヒト成長ホルモン市場2015-2019] (Human Growth Hormone Market in the US 2015-2019 / IRTNTR5538)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆